Litigation Details for Forest Laboratories LLC v. InvaGen Pharmaceuticals Inc. (D. Del. 2015)

Forest Laboratories LLC v. InvaGen Pharmaceuticals Inc. (D. Del. 2015)

Docket		Date Filed	2015-03-27
Court	District Court, D. Delaware	Date Terminated	2017-10-24
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Parties	ALEMBIC GLOBAL HOLDING S/A
Patents	7,834,020; 8,193,195; 8,236,804; 8,673,921
Attorneys	Jennifer Brown
Firms	Phillips, McLaughlin & Hall, P.A.
Link to Docket	External link to docket

Details for Forest Laboratories LLC v. InvaGen Pharmaceuticals Inc. (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-03-27				External link to document
2015-03-27	105		asserted claims of U.S. Patent Nos. 7,834,020 ("the '020 patent"), 8,193,195 ("the…that because claim 1 of U.S. Patent No. 7,834,020, claim 1 of U.S. Patent No. 8,236,804, and claims 5,… ORDER CONSTRUING THE TERMS of U.S. Patent Nos. 7,834,020, 8,193,195, 8,236,804, and 8,673,921. Signed…CONSTRUING THE TERMS OF U.S. PATENT NOS. 7,834,020, 8,193,195, 8,236,804, AND 8,673,921 …the patent. '020 patent, col. 27 ll.42-43; '804 patent, col. 28, 1. 1; '921 patent, col	External link to document
2015-03-27	141		for infringement ofU.S. Patent Nos. 7,834,020 (''the '020 Patent"), 8,193,195 ('…;'the '195 Patent"), 8,236,804 (''the '804 Patent"), and 8,673,921… (''the '921 Patent") (collectively the "Patents in Suit") in connection…the expiration of the Patents in Suit was an act of infringement of the Patents in Suit under 35 U.S.…HOLDINGS, LTD., MERCK ) KGaA and MERCK PATENT GESELLSCHAFT ) MIT BESCHRANKTER	External link to document

Forest Laboratories LLC v. InvaGen Pharmaceuticals Inc. Litigation Summary, 1:15-cv-00272

Last updated: August 2, 2026

Forest Laboratories LLC v. InvaGen Pharmaceuticals Inc., No. 1:15-cv-00272, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware concerning InvaGen's abbreviated new drug application for generic vilazodone hydrochloride, the active pharmaceutical ingredient in Forest's Viibryd antidepressant. The case involved Forest's Orange Book-listed patents covering vilazodone and its use in treating major depressive disorder. The commercial issue was whether InvaGen could obtain FDA approval and launch before the expiration or settlement of Forest's patent rights.

The case was part of Forest's broader generic-defense program for Viibryd. Forest's patent estate created a meaningful barrier to immediate generic entry, but the relevant patents had different expiration dates and varying litigation value. The principal risk to Forest was generic entry after the basic composition and formulation protection expired, particularly if later-listed method-of-use patents could not block a full-label launch.

What drug and patents were at issue in Forest v. InvaGen?

The litigation concerned Viibryd, an oral tablet containing vilazodone hydrochloride. The product was approved by the FDA in January 2011 for the treatment of major depressive disorder in adults. Forest Laboratories developed and commercialized Viibryd before its pharmaceutical business was acquired by Actavis, which was later acquired by Allergan and then AbbVie.[1]

Product and regulatory profile

Item	Detail
Brand	Viibryd
Active ingredient	Vilazodone hydrochloride
Dosage form	Immediate-release oral tablets
Indication	Major depressive disorder in adults
NDA holder at approval	Forest Laboratories LLC
FDA approval	January 21, 2011
Regulatory pathway	New drug application
Litigation pathway	Hatch-Waxman ANDA litigation
District court	U.S. District Court for the District of Delaware
Civil action	No. 1:15-cv-00272

Forest alleged that InvaGen's ANDA filing infringed patents listed for Viibryd under 35 U.S.C. § 271(e)(2). InvaGen's filing would have permitted FDA approval of a generic vilazodone product if the asserted patents were invalid, not infringed, or otherwise did not block approval.

Public patent records associate Viibryd with patents covering vilazodone compositions, pharmaceutical formulations, and methods of treating depression. The relevant Orange Book patent group included U.S. Patent No. 7,834,020 and later patents directed to vilazodone formulations and therapeutic use.[2][3]

What were the principal legal issues?

The case presented the standard issues in an ANDA patent action:

1. Whether InvaGen's ANDA constituted an artificial act of infringement.
2. Whether the asserted Viibryd patents were valid.
3. Whether the proposed generic product would infringe the asserted claims.
4. Whether Forest could obtain an injunction preventing FDA approval or commercial launch.
5. Whether method-of-use claims could block approval for a generic applicant seeking a narrower indication.

The ANDA filing itself supplied the jurisdictional basis for the patent action. Under the Hatch-Waxman framework, Forest could sue within 45 days after receiving InvaGen's Paragraph IV notice. The filing triggered the statutory 30-month stay of FDA approval, subject to court decisions, settlement terms, and regulatory exceptions.[4]

Composition and formulation claims

The composition and formulation claims were the strongest form of protection from a practical enforcement perspective because they could reach the generic product itself. A claim directed to a pharmaceutical composition containing vilazodone, or to a defined tablet formulation, generally presents a direct infringement theory if the ANDA product has the claimed active ingredient and excipients.

The defense would typically focus on claim construction, noninfringement based on excipient or concentration differences, anticipation, obviousness, and enablement. Formulation patents can be commercially important even when the basic active-ingredient patent is close to expiration because they may extend the period during which a generic must design around the branded product.

Method-of-use claims

Viibryd patents also included claims directed to treating depression with vilazodone. Method-of-use patents are more vulnerable to an indication carve-out. A generic applicant may seek approval for uses not covered by the patent and remove protected language from its labeling under the section viii process.

The effectiveness of a carve-out depends on the claim scope, the proposed label, physician prescribing behavior, and whether the patented method is central to the product's approved use. For an antidepressant with a single principal indication, a method-of-use patent may be less commercially effective than a composition or formulation patent if physicians can prescribe the generic for the same clinical condition despite label restrictions.

What was InvaGen's likely Paragraph IV position?

InvaGen's ANDA filing was a Paragraph IV challenge to the listed Viibryd patents. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

The commercial objective of the filing was to obtain an earlier generic entry date than the ordinary expiration date of every relevant patent. InvaGen's litigation position would have been evaluated against:

• The scope of the asserted claims.
• The patent expiration dates and any patent-term adjustment.
• The existence of later-issued formulation or method patents.
• The availability of a label carve-out.
• The economics of entering before or after other generic applicants.
• The risk of an injunction and damages exposure.

A Paragraph IV filing does not itself establish that the generic product will launch. It creates litigation risk for the brand and the applicant. In many pharmaceutical cases, the parties resolve the dispute through a settlement that establishes a future entry date without a merits judgment on validity or infringement.

What was the litigation timeline?

Date	Event
January 21, 2011	FDA approved Viibryd for major depressive disorder.[1]
2015	Forest filed the Delaware action against InvaGen after receiving notice of InvaGen's ANDA challenge.
2015-2016	The parties litigated the asserted Viibryd patent claims under the Hatch-Waxman framework.
Subsequent proceedings	The docket resolved the dispute without a reported trial judgment establishing a broad invalidity ruling against the Viibryd patent estate.
2022	FDA approvals for generic vilazodone products began to appear as the principal commercial patent barriers expired or ceased to prevent approval.[5]

The public docket should be read together with the FDA Orange Book and later FDA product approvals. A civil-action termination does not necessarily mean that all patents were invalidated. It may reflect settlement, dismissal, consent judgment, or resolution of the dispute on terms that are not fully stated in the docket entry.

What was the Orange Book status of Viibryd?

The Orange Book listed patents for Viibryd covering the active ingredient, product formulation, and methods of use. The principal early patent, U.S. Patent No. 7,834,020, had an expiration date in 2022, subject to applicable patent-term calculations.[2]

Later patents extended protection for selected formulations and uses. Their practical value depended on whether the claims covered the generic product as filed and whether the generic applicant could use a label carve-out. Orange Book listing alone does not guarantee that a patent will prevent approval. FDA approval consequences depend on the certification, litigation status, court order, and statutory stay.

Key Orange Book and exclusivity considerations

Protection type	Business effect
New chemical entity exclusivity	Delayed certain ANDA submissions for five years after approval
Composition patent	Can block approval or launch of products containing vilazodone
Formulation patent	May require a generic design-around
Method-of-use patent	May be vulnerable to a section viii label carve-out
30-month stay	Temporarily delayed FDA approval after a timely Paragraph IV suit
Settlement entry date	Could permit launch before the latest patent expiry

Viibryd's five-year new chemical entity exclusivity expired in 2016. That date allowed ANDA applicants to file Paragraph IV certifications, but it did not eliminate the patent barriers. The commercial exclusivity analysis therefore depended primarily on patent expiry and any settlement entry date after 2016.[4]

When did Viibryd lose exclusivity?

Viibryd lost regulatory NCE exclusivity in 2016, but patent protection continued after that date. The earliest significant patent expiration was in 2022. FDA generic approvals for vilazodone began after the core patent barrier had diminished.[2][5]

The distinction matters:

• Regulatory exclusivity controls when an ANDA may be submitted or approved.
• Patent expiry controls whether a generic can lawfully launch.
• A settlement may establish a contractual launch date earlier than the last listed patent expiration.
• A later formulation patent may remain relevant even after the base product patent expires.

The first generic launch scenario therefore depended on the applicant's patent certifications and settlement rights, not solely on the 2016 NCE date.

How strong was Forest's Viibryd patent estate?

Forest's estate was moderate rather than absolute. Its strongest assets were the patents that claimed vilazodone compositions or commercially relevant tablet formulations. Those patents could create direct infringement exposure and were harder to avoid through a label carve-out.

The weaker assets were narrow method-of-use claims. Their blocking effect depended on the language of the proposed generic label and the availability of a carve-out. A method patent directed to the principal approved indication can still create litigation risk, but it may not support a complete commercial block if the generic label omits the patented language.

Strength assessment

Patent category	Relative blocking strength	Primary vulnerability
Vilazodone composition claims	High	Validity, claim scope, prior art
Tablet formulation claims	Medium to high	Design-around and obviousness
Method-of-use claims	Medium	Section viii carve-out
Narrow dosing claims	Low to medium	Label modification and noninfringement
Later-issued patents	Variable	Whether they read on the ANDA product

The estate's main limitation was timing. Once the core patents approached expiration, the value of a successful defense declined. The brand could preserve a premium only if later patents covered the marketed product and survived validity and infringement challenges.

Did Forest v. InvaGen produce a Paragraph IV judgment?

No reported merits decision from the case established that InvaGen's generic product infringed a valid Viibryd patent. The litigation record is therefore more useful as an indicator of generic-entry risk than as precedent establishing the validity of the asserted patents.

The absence of a reported trial judgment means the case should not be characterized as a Forest victory on patent validity. The relevant commercial result was the timing of generic approval and launch, together with any confidential or nonpublic settlement terms.

Were there licensing or settlement agreements?

The public case record does not provide a complete public description of commercial settlement terms. A docket disposition alone does not establish whether the parties agreed to:

• A fixed generic entry date.
• An authorized generic arrangement.
• A license to Forest's patents.
• A waiver of damages.
• Restrictions on launch, manufacturing, or distribution.
• A settlement payment or other consideration.

No public record should be treated as proving a reverse-payment settlement unless the agreement, FTC filing, court order, or other authoritative source identifies those terms. The case should therefore be classified as a resolved Hatch-Waxman dispute rather than as a litigated invalidity precedent.

What generic entry risks existed for Forest?

Forest faced four principal risks.

First, InvaGen could have prevailed on invalidity. Obviousness was the central vulnerability for later formulation and use claims, particularly if the prior art disclosed vilazodone, conventional tablet excipients, and routine dosing approaches.

Second, InvaGen could have prevailed on noninfringement through a product design-around. A generic applicant can modify excipients, release characteristics, dosage strengths, or label language to avoid asserted claims.

Third, InvaGen could have launched after a favorable court ruling or at-risk before final judgment. An at-risk launch would have exposed InvaGen to potential damages and an injunction, but it could have accelerated price erosion for Viibryd.

Fourth, another ANDA applicant could have entered earlier. Generic competition is often determined by the first applicant with enforceable exclusivity or a favorable settlement, not by the defendant that files the most aggressive challenge.

How did Viibryd compare with competing antidepressant patent estates?

Viibryd had a narrower commercial market than major selective serotonin reuptake inhibitors, but its patent estate was structurally similar to other small-molecule antidepressant products. The basic molecule and formulation patents provided the principal protection. Method-of-use patents supplied incremental protection but were less reliable against a generic label carve-out.

Unlike a biologic, vilazodone did not benefit from a complex manufacturing process that could create a separate, difficult-to-replicate barrier. Generic applicants could rely on the ANDA pathway and demonstrate pharmaceutical equivalence and bioequivalence rather than reproduce a biologic manufacturing platform.

What manufacturing and geographic barriers remained?

The case did not create a durable manufacturing barrier comparable to a biologic or complex sterile product. Vilazodone tablets are conventional oral solid dosage forms. The principal barriers were patent rights, FDA approval requirements, bioequivalence, formulation development, and commercial scale-up.

The patent rights were primarily U.S.-specific. A Delaware judgment or settlement would not determine patent rights in Europe, Canada, Japan, or other markets. Generic entry in those jurisdictions depended on local patents, regulatory exclusivity, national litigation, and local settlement terms.

What was the revenue exposure from generic vilazodone?

Forest's revenue exposure was concentrated in the period before generic entry. Once multiple vilazodone suppliers entered, the product would face rapid price erosion typical of conventional oral generics. The severity would depend on:

• The number of approved suppliers.
• Whether an authorized generic launched.
• Pharmacy benefit-manager substitution.
• Wholesaler inventory.
• Generic launch timing relative to competing antidepressants.
• The presence of competing branded therapies.

The patent case protected the opportunity to delay generic erosion, but it could not preserve branded pricing after broad generic substitution became available.

Key Takeaways

• Forest Laboratories sued InvaGen in Delaware over an ANDA for generic vilazodone, the active ingredient in Viibryd.
• The case was a Hatch-Waxman Paragraph IV action, not a biologic or biosimilar dispute.
• Viibryd's NCE exclusivity expired in 2016, while core patent protection extended into 2022.
• Composition and formulation claims presented the strongest blocking positions.
• Method-of-use claims were more exposed to label carve-outs.
• The public record does not establish a reported merits judgment invalidating or upholding the full Viibryd patent estate.
• The case should be analyzed through the combined record of the district-court docket, Orange Book listings, FDA approvals, and any available settlement materials.
• Generic entry risk became substantial as the core patents approached expiration and FDA approved generic vilazodone products.

FAQs About Forest Laboratories v. InvaGen Pharmaceuticals

What was the drug in Forest Laboratories v. InvaGen Pharmaceuticals?

The case concerned generic vilazodone hydrochloride, the active ingredient in Forest Laboratories' Viibryd antidepressant.

Was Forest v. InvaGen a biosimilar case?

No. It was a small-molecule Hatch-Waxman ANDA case involving a conventional oral tablet, not a biosimilar application under the Biologics Price Competition and Innovation Act.

What did InvaGen's Paragraph IV certification challenge?

InvaGen challenged Forest's listed patents for Viibryd, asserting that the patents were invalid, not infringed, or otherwise would not block approval of InvaGen's generic product.

Did the case establish that Viibryd patents were invalid?

No reported merits decision from the case established broad invalidity of the Viibryd patent estate.

When could generic vilazodone enter the U.S. market?

The core Viibryd patent barrier reached expiration in 2022, and FDA generic approvals began around that period. Actual launch timing depended on each applicant's patent certifications, litigation resolution, and any settlement restrictions.

References

1. U.S. Food and Drug Administration. (2011). FDA approves Viibryd to treat major depressive disorder. https://www.fda.gov
2. U.S. Food and Drug Administration. (2022). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
3. U.S. Patent and Trademark Office. (n.d.). Patent Center and Patent Examination Data System records for vilazodone patents. https://patentscenter.uspto.gov
4. U.S. Code. (2023). 35 U.S.C. § 271(e)(2); 21 U.S.C. § 355(j). https://uscode.house.gov
5. U.S. Food and Drug Administration. (2022). FDA approved drug products containing vilazodone hydrochloride. https://www.accessdata.fda.gov/scripts/cder/daf/